Driving Operational Excellence in Immuno-Oncology: How Scancell Uses RIVIA to Power Real-Time Study Execution

Background

Clinical development remains fundamentally resource-intensive. As Dr. Nermeen describes, running a trial properly means navigating “numerous processes” and engaging a wide ecosystem of stakeholders across science, operations, data, and governance.

To move efficiently, Scancell needed modern tools that leverage machine learning, artificial intelligence, and advanced analytics to unify data and surface insights faster.

“Having tools which use the latest capabilities in machine learning, artificial intelligence, data analytics to help bring together these data points more efficiently is hugely valuable, and these tools will become even more valuable as time goes on.”

RIVIA enables Scancell to do just that.

How Rivia Helped

Verified, High-Integrity Data for Leadership and Investors

One of the most immediate benefits was the ability to produce clean, verified data cuts suitable for board discussions, investor engagement, and future fundraising.

“RIVIA has enabled us to get verified high-integrity data cuts that I’ve been able to share with our board, investors, shareholders, as well as future potential investors.”

This transparency and confidence strengthen clinical governance while accelerating strategic decision-making.

Identifying Optimal Product, Patient Populations, and Dosing

With integrated data, Scancell could examine emerging clinical patterns more efficiently and identify combinations most likely to deliver durable responses.

“We’ve been able to understand what is the best combination of product, patient population and dosing that will enable us to get this very important, valuable, durable response.”

This clarity helps the team prioritize paths with the highest therapeutic promise.

Accelerating Development Without Increasing Resource Burden

Both leaders highlighted a key outcome: speed without additional resource consumption.

“We’ve been able to progress at much greater speed than otherwise we would have, without additional consumption of our limited resources.”

The efficiencies gained from real-time data access and automation translate directly into faster trial execution.

Real-Time QTL Monitoring & Risk Management

Joe emphasized RIVIA’s value in identifying operational risks earlier and more reliably.

Early detection of missed IMP doses

Sites may delay or cancel vaccine administration due to toxicities or scheduling challenges. RIVIA flags these issues before manual reports arrive.

“Being able to identify these potentially before sites have even informed us enables us to support the trial site with rescheduling of that vaccine dose at a later date.”

Instant visibility into missed samples

For time-sensitive biomarkers and immunogenicity reads, missed samples can threaten data completeness.

“Being able to detect whether or not those have been picked up is incredibly important, because if a sample is missed, we can ask them to perform that at a later datenot too far away from when it should have been scheduled.”

This real-time monitoring protects data quality and reduces protocol deviations.

A Better Way to Work

Beyond efficiencies, both Nermeen and Joe highlighted how RIVIA improves the human experience of running trials.

“Apart from enabling us to conduct these what can be tedious, painful tasks, it has also been a very pleasant way of doing it, with the huge value of being able to observe and monitor the efforts that the team is putting in.”

RIVIA supports not only operational performance but also team alignment and visibility.

‍

Results

Faster Time to Market Through Big Data & AI

By enabling earlier insight generation and smoother execution, RIVIA supports Scancell’s core mission: bringing cancer vaccines to patients sooner.

“The outcome of Big Data AI really means a quicker time to market, and thus patients are getting access to a medicine much more quickly than they otherwise would.”

Higher Integrity Data for Strategic and Investor Communications

Leadership can rely on verified, trusted data to guide decisions and articulate value to stakeholders.

Real-Time Operational Clarity

Missed doses, toxicities, and missed samples are flagged instantly—shifting the team from reactive to proactive.

Greater Speed Without Additional Resources

Scancell moves faster while preserving precious team bandwidth, a critical advantage for growing biotech organizations.

‍

Looking Ahead

Scancell’s experience shows how modern, AI-enabled clinical platforms can transform the way oncology trials are run: improving data quality, accelerating timelines, and amplifying the impact of small, high-performing teams.

‍

‍